In vitro Analysis of a Synthetic Protein: A Model for Enzyme Replacement Therapy
CSEF · 2010 Biochemistry/ Molecular Biology First Award
Overview
Objectives/Goals My first objective was to determine if a glycine serine linker could be used to attach an Insulin-like Growth Factor 2 (IGF2) tag to the enzyme alpha-N-acetylglucosaminidase (NAGLU) to create a NAGLU-IGF2 fusion protein that retains NAGLU's enzymatic activity. My second objective was to determine if the IGF2 tag improves uptake of synthetic NAGLU by cells. Methods/Materials A plasmid coding for the production of the NAGLU-IGF2 fusion enzyme with a glycine serine linker was created, amplified in E. coli cells, extracted and screened by gel electrophoresis. DNA sequencing verified correct construction of the plasmid. The plasmid was transfected into Chinese hamster ovary (CHO) cells to express the NAGLU-IGF2 enzyme. CHO cells were subcloned. The CHO cell growth medium was collected and assayed using Western blots and enzymatic activity assays. NAGLU-IGF2 was purified from the CHO cell growth medium using Concanvalin-A and c-Myc affinity columns. Human fibroblasts deficient in NAGLU were treated with purified NAGLU-IGF2 and lysed open to measure cellular uptake of the fusion enzyme. Results Western blots confirm that NAGLU-IGF2 is successfully produced and purified. Enzymatic activity assays reveal that NAGLU-IGF2 has enzymatic activity. Uptake assays show that NAGLU-IGF2 can enter human fibroblasts. Conclusions/Discussion My previous two years of research showed that attaching the IGF2 tag directly to NAGLU caused NAGLU to lose its enzymatic activity. The glycine serine linker has allowed the IGF2 tag to be attached to NAGLU and preserve NAGLU's ability to bind with its substrate, as hypothesized. Furthermore, the IGF2 tag improves NAGLU's cellular uptake, in comparison to a negative control: synthetic NAGLU without the IGF2 tag. As created by my project, NAGLU-IGF2 could potentially be used as enzyme replacement therapy for Sanfilippo B syndrome, a genetic disorder resulting in the body's inability to produce NAGLU.
Summary statement
My project uses recombinant DNA techniques to create a NAGLU-IGF2 fusion protein and characterizes it.
Help received
Used lab equipment at Los Angeles Biomedical Research Institute with mentoring by Patricia Dickson, MD
Awards (1)
Competition history
- CSEF 2010
Resources
Related projects
CSEF · 2008
Construction of an IGF-NAGLU Fusion Protein for Treatment of Sanfilippo B Syndrome
CSEF · 2013
Expression and Identification of N-acetylglucosamine-6-sulfatase (GNS): A Potential ERT Drug for Sanfilippo Syndrome D
CSEF · 2006
Synthesis and Biological Evaluation of a Glycoprotein as Antibacterial Agent
CSEF · 2017
Developing a Tool for Studying Alzheimer's: A Bacterial Expression Vector for the M3-M4 Fragment of the nAChR alpha-7
CSEF · 2004
The Study of A3174 G and G3877A Double Mutation in the 3' UTR of the SRD5A2 Gene
CSEF · 2017
Creating a More Efficient Cellulase for Biofuel Production
CSEF · 2013
The Effect of Amino Acid Mutations on the Refolding of Thrombomodulin
CSEF · 2017
Hormonal Regulation of Hexosaminidase: Implications for Tay-Sachs Disease
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: California Science & Engineering Fair public projects